Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.87
(
0.68%
)
Bitcoin
68,623.90
(
1.16%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: go seek post# 8278

Thursday, 02/21/2008 3:34:27 PM

Thursday, February 21, 2008 3:34:27 PM

Post# of 19309
>it is my understanding this [phase-2 DIC] study is a dosing range study, and is not set up for efficacy results. What could we learn from the P2 study that will be of interest to the investment community?<

It’s a typical phase-2 study. It will measure efficacy but is not powered to detect a statsig difference in survival. The main thing to be learned is whether the drug works well enough to advance the DIC program to phase-3.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today